Stelara-话题@MedSci - 梅斯（MedSci）

#Stelara#

12篇内容 | 1766人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1250899, encodeId=5690125089957, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, objectType=article, longId=213917, objectId=365621391e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365621391e66, replyNumber=0, likeNumber=0, createdTime=2021-07-10, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365621391e66, moduleTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=365621391e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250898, encodeId=4bc1125089849, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=95, createdTime=2020-08-03, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250897, encodeId=40ff125089e69, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=62, createdTime=2020-06-29, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250896, encodeId=d75b125089694, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, objectType=article, longId=196065, objectId=c775196065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c775196065fc, replyNumber=0, likeNumber=78, createdTime=2020-06-19, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c775196065fc, moduleTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c775196065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250895, encodeId=6e0912508955d, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, objectType=article, longId=195937, objectId=b9d319593e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d319593e23, replyNumber=0, likeNumber=78, createdTime=2020-06-17, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d319593e23, moduleTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b9d319593e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250894, encodeId=9b9c125089423, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=87, createdTime=2020-02-17, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250893, encodeId=b9e0125089367, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, objectType=article, longId=187183, objectId=a1b618e18333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b618e18333, replyNumber=0, likeNumber=74, createdTime=2020-02-03, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b618e18333, moduleTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a1b618e18333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250892, encodeId=0abc125089264, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=57, createdTime=2019-10-23, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250891, encodeId=4055125089119, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎, objectType=article, longId=176378, objectId=18ff1e63783f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff1e63783f, replyNumber=0, likeNumber=0, createdTime=2019-07-30, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff1e63783f, moduleTitle=CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=18ff1e63783f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250890, encodeId=bf121250890ec, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, objectType=article, longId=85676, objectId=152b856e6bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152b856e6bf, replyNumber=0, likeNumber=60, createdTime=2016-12-29, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152b856e6bf, moduleTitle=强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=152b856e6bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250889, encodeId=51291250889a3, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90), objectType=article, longId=64414, objectId=a3da64414ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3da64414ca, replyNumber=0, likeNumber=71, createdTime=2016-03-09, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3da64414ca, moduleTitle=诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a3da64414ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1250888, encodeId=2eca125088825, content=<a href='/topic/show?id=373016e75c0' target=_blank style='color:#2F92EE;'>#Stelara#</a>, objectTitle=强生单抗药Stelara获加拿大批准, objectType=article, longId=29875, objectId=8442298e51c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8442298e51c, replyNumber=0, likeNumber=75, createdTime=2014-01-25, rootId=0, userName=gj0731, userId=f76619, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8442298e51c, moduleTitle=强生单抗药Stelara获加拿大批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8442298e51c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Stelara

2020-05-29

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究

2021-07-10

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-08-03

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2020-06-29

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎

2020-06-19

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率

2020-06-17

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-02-17

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

2020-02-03

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2019-10-23

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎

2019-07-30

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

强生向美国FDA提交重磅抗炎药Stelara补充生物制品许可（sBLA），治疗青少年斑块型银屑病

2016-12-29

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90)

2016-03-09

gj0731 (审核中...)

前往app查看评论内容

#Stelara#

强生单抗药Stelara获加拿大批准

2014-01-25

科室
- - 订阅+
  - 更多科室
工具
服务